Who
Matthias Bodenstedt
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, MoonLake Immunotherapeutics.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 9
- Bought
- $99K
- Sold
- $12.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Apr 2023
- Last trade
- 22 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 23 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $862K39,120 at $22.04 | filing |
| 22 Jun 2026filed 23 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $862K39,120 at $22.04 | filing |
| 18 Jun 2026filed 18 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $55K2,794 at $19.60 | filing |
| 18 Jun 2026filed 18 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $55K2,794 at $19.60 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $297K15,082 at $19.68 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $297K15,082 at $19.68 | filing |
| 11 May 2026filed 13 May 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $273K13,653 at $20.02 | filing |
| 11 May 2026filed 13 May 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $273K13,653 at $20.02 | filing |
| 14 Apr 2026filed 16 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $47K2,426 at $19.56 | filing |
| 14 Apr 2026filed 16 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $47K2,426 at $19.56 | filing |
| 10 Apr 2026filed 10 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $38K1,925 at $19.51 | filing |
| 10 Apr 2026filed 10 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $38K1,925 at $19.51 | filing |
| 9 Apr 2026filed 10 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M85,870 at $18.94 | filing |
| 9 Apr 2026filed 10 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M85,870 at $18.94 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code A | —354,296 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code A | —354,296 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —8,754 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code C | —294,473 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code D | —294,473 | filing |
| 8 Oct 2025filed 9 Oct 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Bought | $99K10,870 at $9.09 | filing |
News
No headline names them, or the companies they trade most, lately.